Leukocyte cell therapy - Leap Therapeutics

Drug Profile

Leukocyte cell therapy - Leap Therapeutics

Alternative Names: CureXcell

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroCure
  • Developer Leap Therapeutics
  • Class Cell therapies; Skin disorder therapies
  • Mechanism of Action Growth substance stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic wounds; Skin ulcer
  • No development reported Diabetic foot ulcer; Leg ulcer

Most Recent Events

  • 23 Jan 2017 MacroCure has been acquired and merged into Leap Therapeutics
  • 12 May 2015 Phase-III development for Diabetic foot ulcer is ongoing in USA, Canada and Israel
  • 11 May 2015 MacroCure completed enrolment in a phase III trial for Leg ulcer (Adjunctive treatment) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top